Table 2 Ocular complications secondary to proteasome inhibitor therapy for sixteen patients with plasma cell disorders
From: Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series
Ocular complications by diagnosis (n = 24): | |
Chalazion | 14 (87.5%) |
Blepharitis | 10 (62%) |
Ocular complications by episode (n = 34): | |
Chalazion | 23 (68%) |
Blepharitis | 11 (32%) |
Ocular complications by patient (n = 16): | |
Chalazion only | 6 (37.5%) |
Blepharitis only | 2 (12.5%) |
Chalazion + blepharitis | 8 (50%) |
Chemotherapy-associated eyelid complication characteristics: | |
Patients with chalazia (n) | 14 |
Episodes of chalazia (n) | 23 |
Patients with 2+ chalazia at single episode (n) | 11 (79%) |
Average chalazia at most severe episode (range) | 2.7 (1–6) |
Average chalazion size in mm (range) | 5.4 (2–5) |
Average total affected eyelids (range) | 2.4 (1–4) |
Total chalazia in cohort (n) | 46 |
Upper eyelid chalazia | 32 (70%) |
Lower eyelid chalazia | 14 (30%) |
Laterality | |
Bilateral chalazia (episodes) | 12 (52%) |
Unilateral chalazia (episodes) | 11 (48%) |
Bilateral blepharitis (episodes) | 9 (82%) |
Unilateral blepharitis (episodes) | 1 (9%) |
Blepharitis laterality unknown (episodes) | 1 (9%) |